BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
BioLineRx (NASDAQ: BLRX) has launched 'Mobilization Matters', a digital resource for multiple myeloma patients preparing for stem cell collection. The platform, launched on Apheresis Awareness Day, offers patient stories, educational resources, and a discussion guide to support patients undergoing this critical treatment phase.
In partnership with the HealthTree Foundation, BioLineRx is conducting the Mobilization Matters Stem Cell Collection Survey to gather patient insights about their experiences with stem cell collection and apheresis. Survey results are expected in Q1 2025. The initiative aims to enhance understanding and improve care strategies for multiple myeloma patients undergoing stem cell collection.
BioLineRx (NASDAQ: BLRX) ha lanciato 'Mobilization Matters', una risorsa digitale per pazienti affetti da mieloma multiplo che si preparano alla raccolta di cellule staminali. La piattaforma, lanciata in occasione della Giornata di Consapevolezza dell'Aferesi, offre storie dei pazienti, risorse educative e una guida alla discussione per supportare i pazienti durante questa fase critica del trattamento.
In collaborazione con la HealthTree Foundation, BioLineRx sta conducendo il Mobilization Matters Stem Cell Collection Survey per raccogliere informazioni dai pazienti riguardo alle loro esperienze con la raccolta di cellule staminali e l'aferesi. I risultati del sondaggio sono attesi per il Q1 2025. L'iniziativa mira a migliorare la comprensione e le strategie di cura per i pazienti affetti da mieloma multiplo che stanno subendo la raccolta di cellule staminali.
BioLineRx (NASDAQ: BLRX) ha lanzado 'Mobilization Matters', un recurso digital para pacientes con mieloma múltiple que se preparan para la recolección de células madre. La plataforma, lanzada en el Día de Concientización sobre Aferesis, ofrece historias de pacientes, recursos educativos y una guía de discusión para apoyar a los pacientes que atraviesan esta fase crítica del tratamiento.
En colaboración con la Fundación HealthTree, BioLineRx está realizando la Encuesta sobre la Recolección de Células Madre Mobilization Matters para recopilar información de los pacientes sobre sus experiencias con la recolección de células madre y aferesis. Se esperan resultados de la encuesta para el Q1 2025. La iniciativa tiene como objetivo mejorar la comprensión y las estrategias de atención para los pacientes con mieloma múltiple que se someten a la recolección de células madre.
BioLineRx (NASDAQ: BLRX)는 줄기 세포 수집을 준비하는 다발성 골수종 환자를 위한 디지털 자원인 'Mobilization Matters'를 출시했습니다. 이 플랫폼은 환자 이야기, 교육 자료 및 토론 가이드를 제공하여 이 중요한 치료 단계를 겪고 있는 환자를 지원합니다.
BioLineRx는 HealthTree Foundation과 협력하여 Mobilization Matters 줄기 세포 수집 설문조사를 실시하여 환자들이 줄기 세포 수집 및 아페레시스에 대해 겪은 경험에 대한 통찰력을 수집하고 있습니다. 설문조사 결과는 2025년 1분기에 발표될 예정입니다. 이 이니셔티브는 줄기 세포 수집을 받고 있는 다발성 골수종 환자에 대한 이해를 높이고 치료 전략을 개선하는 것을 목표로 하고 있습니다.
BioLineRx (NASDAQ: BLRX) a lancé 'Mobilization Matters', une ressource numérique pour les patients atteints de myélome multiple se préparant à la collecte de cellules souches. La plateforme, lancée à l'occasion de la Journée de Sensibilisation à l'Aphérèse, offre des témoignages de patients, des ressources éducatives et un guide de discussion pour soutenir les patients en phase de traitement critique.
En partenariat avec la HealthTree Foundation, BioLineRx mène l'Enquête sur la Collecte de Cellules Souches Mobilization Matters pour recueillir des informations sur les expériences des patients concernant la collecte de cellules souches et l'aphérèse. Les résultats de l'enquête sont attendus pour le Q1 2025. L'initiative vise à améliorer la compréhension et les stratégies de soins pour les patients atteints de myélome multiple subissant une collecte de cellules souches.
BioLineRx (NASDAQ: BLRX) hat 'Mobilization Matters' gestartet, eine digitale Ressource für Patienten mit multiples Myelom, die sich auf die Sammlung von Stammzellen vorbereiten. Die Plattform, die am Apherese-Tag gestartet wurde, bietet Patientengeschichten, Bildungsressourcen und einen Diskussionsleitfaden, um Patienten in dieser kritischen Behandlungsphase zu unterstützen.
In Zusammenarbeit mit der HealthTree Foundation führt BioLineRx die Mobilization Matters Stammzellen-Sammelumfrage durch, um die Erfahrungen der Patienten mit der Stammzellensammlung und Apherese zu erfassen. Die Ergebnisse der Umfrage werden für Q1 2025 erwartet. Die Initiative zielt darauf ab, das Verständnis zu verbessern und die Pflegepläne für Patienten mit multiplen Myelom, die sich einer Stammzellensammlung unterziehen, zu optimieren.
- Launch of 'Mobilization Matters' digital resource for multiple myeloma patients
- Partnership with HealthTree Foundation for patient survey
- Potential for improved patient care strategies based on survey insights
- None.
Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025
In conjunction with this launch, BioLineRx is partnering with the HealthTree Foundation to conduct the Mobilization Matters Stem Cell Collection Survey. This initiative aims to gather insights from patients about their experiences with stem cell collection and apheresis as part of their multiple myeloma journey. The findings will help illuminate patient experiences, enhance understanding, and improve care and support strategies. Survey results are expected in Q1 2025.
"We are deeply committed to supporting multiple myeloma patients and their care partner through their stem cell collection process," said Holly May, MBA, President of BioLineRx
In addition to patient stories and survey information, Mobilization Matters features a discussion guide to facilitate conversations between patients and their healthcare teams before apheresis. For more information, visit www.mobilizationmatters.com.
About the Mobilization Matters Survey
The Mobilization Matters Stem Cell Collection Survey is being conducted by the HealthTree Foundation on behalf of BioLineRx among adults with multiple myeloma (ages 18+) who have attempted stem cell collection for a planned transplant. Developed in collaboration with experts from leading institutions and patient advisors, the survey aims to provide valuable insights into the emotional, physical, and daily life challenges patients face during the stem cell collection process. Results will be shared on mobilizationmatters.com, once available.
"This survey will provide important insights into the patient experience with stem cell collection, offering a deeper understanding of the potential challenges involved," said Beth B. Giblin, PharmD, Head of US Medical Affairs, BioLineRx. "Our aim is to use the findings to build on the existing literature and inform data-driven approaches to patient care and support."
"We need to better understand the patient's journey during the stem cell collection process," said Jenny Ahlstrom, Founder & CEO of the HealthTree Foundation. "We are excited to use these data to advance education and drive patient-centered care. This collaboration supports our mission to empower multiple myeloma patients with knowledge, enhance their care experiences, and contribute meaningfully to research."
This survey marks the first patient experience study by the HealthTree Foundation on this critical topic. The research is being conducted through the HealthTree Cure Hub, a patient-data platform and community with over 14,000 registered myeloma patients, where participants can opt into surveys and studies to accelerate research and shape the future of healthcare.
About Stem Cell Mobilization for Multiple Myeloma
Autologous stem cell transplantation (ASCT) is the preferred first-line treatment for multiple myeloma – the second most common blood cancer – and is integral to the prospect of improving survival and helping to restore the immune system.i,ii
Prior to ASCT, patients undergo apheresis, a procedure to collect stem cells for transplant. Stem cells are made deep in the bone marrow and need to be mobilized from the bone marrow to the bloodstream for collection during apheresis.iii,iv
ASCT success depends on adequate mobilization and collection of stem cells.iii While more multiple myeloma patients are candidates for ASCT than ever before, stem cell mobilization and collection is a growing challenge. This is due to factors such as increasing proportion of older patients receiving ASCTvi and the use of standard 3- and 4-drug induction therapy, which can further impair mobilization with fewer cells mobilized and additional days of apheresis required.vii, viii
About the HealthTree Foundation
HealthTree is a global nonprofit using innovation to save lives. They provide lifetime personalized support and education, meaningful patient-to-patient connections and a powerful patient data portal. HealthTree's cutting-edge technology empowers patients to better manage their health and engages them as critical contributors to lifesaving research. The trust of their patient community allows HealthTree to provide continually updated, real-world patient data to researchers who seek to advance clinical care and find cures for blood cancers. Visit healthtree.org today.
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. Since receiving approval for our first marketed product in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.
Logo: https://mma.prnewswire.com/media/2154863/4858892/BioLineRx_Ltd_Logo.jpg
i Dhakal B, et al. Transplant Cell Ther. 2022;28(6):284-293.
ii Kumar SK, et al. Blood. 2008;111(5):2516-2520.
iii Giralt S, Costa L, Schriber J, et al. Biol Blood Marrow Transplant. 2014;20(3):295-308.
iv American Cancer Society. Types of Stem Cell and Bone Marrow Transplants.
v Swan D, Hayden PJ, Eikema D-J, et al. BR J Haematol. 2022;197(1):82-96.
vi Morris CL, Siegel E, Barlogie B, et al. Br J Haematol. 2003;120(3):413-423.
vii Hulin C, Offner F, Moreau P, et al. Haematologica. 2021;106(8):2257-2260.
viii Chhabra S, Callander N, Watts NL, et al. Transplant Cell Ther. 2023;29(3):174.e1-174.e10.
CONTACTS:
John Lacey
BioLineRx
IR@biolinerx.com
View original content:https://www.prnewswire.com/news-releases/biolinerx-launches-mobilization-matters-a-digital-resource-for-people-with-multiple-myeloma-preparing-for-stem-cell-collection-302250690.html
SOURCE BioLineRx Ltd.
FAQ
What is 'Mobilization Matters' launched by BioLineRx (BLRX)?
When are the results of the Mobilization Matters Stem Cell Collection Survey expected for BioLineRx (BLRX)?
What is the purpose of the Mobilization Matters Stem Cell Collection Survey by BioLineRx (BLRX)?
On which day did BioLineRx (BLRX) launch the 'Mobilization Matters' platform?
